University of Illinois at Chicago
Announcement of an Exempt Purchase
Awarded to:Vendor: QuVa Pharma Inc., Sugar Land, TX
Amount: An estimated $600,000
Terms:
An estimated start date of 7/14/2020 through 6/30/2023
Renewals:
None
The University award process may be delayed up to thirty days as this award goes through a state approval process.
First published Tuesday, July 14, 2020
The University awarded a contract for 503b compounding products.
QuVa Pharma is a 503b supplier providing pre-made compounding products. These compounds include many different medications used in surgical areas such as compound syringes of labetalol, succinylcholine, lidocaine, phenylephrine, epinephrine, and many other compunds including IV bags, that are ready to use in the operating room.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) Our previous 503B compounding facility has closed and no longer offers compounded products to hospitals. QuVa is on the Vizient contract, it produces the products we need in the correct strengths/volumes and most importantly, it has capacity to immediately start providing us product.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire
qualified veterans, minorities, females, persons with disabilities and ex-offenders.
